Ben-Gurion University researchers have partnered Israel’s OncoHost to develop a biosensor that safely predicts if anti-PD1 therapy may cure a specific cancer patient. The leading immune checkpoint inhibitor (ICI) therapy is invasive and other treatments may be better. (see also here).

https://in.bgu.ac.il/en/pages/news/elkabets_porgador_immunotherapy.aspx

https://nocamels.com/2023/06/cancer/

https://www.science.org/doi/10.1126/sciadv.adg2809

https://www.timesofisrael.com/new-technology-improves-prediction-of-patient-response-to-immunotherapy/